-
Electronic (PDF)
-
Site License
-
Enterprisewide
Javelin Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010
GlobalData, November 2010, Pages: 46
Javelin Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “Javelin Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Javelin Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Javelin Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Javelin Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Javelin Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Javelin Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Javelin Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Javelin Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Javelin Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Javelin Pharmaceuticals, Inc. and identify potential opportunities in those areas.
List of Tables
List of Figures
Javelin Pharmaceuticals, Inc. Snapshot
Javelin Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Javelin Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Javelin Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Javelin Pharmaceuticals, Inc. – Pipeline Products Glance
Javelin Pharmaceuticals, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Javelin Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Javelin Pharmaceuticals, Inc. – Drug Profiles
Dyloject
Product Description
Mechanism of Action
R&D Progress
Ereska
Product Description
Mechanism of Action
R&D Progress
Rylomine
Product Description
Mechanism of Action
R&D Progress
Rylomine
Product Description
Mechanism of Action
R&D Progress
Javelin Pharmaceuticals, Inc. – Pipeline Analysis
Javelin Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Javelin Pharmaceuticals, Inc. Pipeline Products By Target
Javelin Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Javelin Pharmaceuticals, Inc. – Company Statement
Javelin Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Feb 17, 2010: Javelin Pharmaceuticals Receives FDA PDUFA Date For Dyloject NDA
Feb 11, 2010: Javelin Announces Top Line Phase III Results Of Ereska From Re-Examination Conducted By Third Party
Feb 02, 2010: FDA Accepts Javelin Pharmaceuticals' Dyloject New Drug Application For Formal Review
Dec 02, 2009: Javelin Pharmaceuticals Files New Drug Application Of Dyloject With FDA For Management Of Acute Moderate-To-Severe Pain
Jun 10, 2008: Enrolls First Patient In Pivotal Trial For PMI-150
Dec 14, 2007: Javelin Pharmaceuticals Announces Successful Dyloject Pivotal US Phase 3 Trial Top-Line Results at New York City Analyst Day
Jul 31, 2007: Javelin Pharmaceuticals Initiates Phase 3 Breakthrough Cancer Pain Trial For Intranasal Ketamine
Oct 12, 2005: Phase IIb Study Data Demonstrate Rylomine Significantly Reduces Postsurgical Orthopedic Pain
Jul 01, 2005: Javelin Announces Acceptance Of Marketing Authorization Application (MAA) For European Regulatory Approval Of Dyloject.
Financial Deals Landscape
Javelin Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Javelin Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Javelin Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Javelin Pharmaceuticals, Inc. Detailed Deal Summary
Acquisition
Myriad Pharmaceuticals Terminates Acquisition Of Javelin Pharmaceuticals
Equity Offering
Javelin Pharmaceuticals Completes Private Placement Of $4 Million
Javelin Completes Private Placement Of $27.53 Million
Javelin Completes Public Offering Of $45.3 million
Javelin Completes Private Placement Of $32 Million
Licensing Agreements
Javelin Enters Into Licensing Agreement With Therabel For Dyloject
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
